Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5291465
Max Phase: Preclinical
Molecular Formula: C74H102N8O10
Molecular Weight: 1263.68
Associated Items:
ID: ALA5291465
Max Phase: Preclinical
Molecular Formula: C74H102N8O10
Molecular Weight: 1263.68
Associated Items:
Canonical SMILES: C[C@H](CCC(=O)OCc1cn([C@@H]2C(=O)N(CCN3C(=O)[C@@H](n4cc(COC(=O)CC[C@@H](C)[C@H]5CC[C@H]6[C@@H]7CC[C@@H]8C[C@H](O)CC[C@]8(C)[C@H]7C[C@H](O)[C@]56C)nn4)[C@H]3c3ccccc3)[C@@H]2c2ccccc2)nn1)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
Standard InChI: InChI=1S/C74H102N8O10/c1-43(55-23-25-57-53-21-19-47-35-51(83)29-31-71(47,3)59(53)37-61(85)73(55,57)5)17-27-63(87)91-41-49-39-81(77-75-49)67-65(45-13-9-7-10-14-45)79(69(67)89)33-34-80-66(46-15-11-8-12-16-46)68(70(80)90)82-40-50(76-78-82)42-92-64(88)28-18-44(2)56-24-26-58-54-22-20-48-36-52(84)30-32-72(48,4)60(54)38-62(86)74(56,58)6/h7-16,39-40,43-44,47-48,51-62,65-68,83-86H,17-38,41-42H2,1-6H3/t43-,44-,47-,48-,51-,52-,53+,54+,55-,56-,57+,58+,59+,60+,61+,62+,65-,66-,67+,68+,71+,72+,73-,74-/m1/s1
Standard InChI Key: VYCWAOBGZBJDAG-ZXKAVVQPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1263.68 | Molecular Weight (Monoisotopic): 1262.7719 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Fu DJ, Zhang YF, Chang AQ, Li J.. (2020) β-Lactams as promising anticancer agents: Molecular hybrids, structure activity relationships and potential targets., 201 [PMID:32592915] [10.1016/j.ejmech.2020.112510] |
Source(1):